APOD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the APOD gene. This polyclonal knockout product contains a heterogeneous mixture of edited cells, enabling functional genomics studies without clonal selection. The CRISPR/Cas9-mediated gene ablation eliminates apolipoprotein D expression, providing a loss-of-function model to investigate APOD-dependent signaling and lipid transport processes in a relevant cancer background.
The A-549 cell line, established from a human lung adenocarcinoma, exhibits adherent epithelial morphology and retains characteristics of alveolar type II pneumocytes. Widely used as a model for non-small cell lung carcinoma, A-549 cells are genetically tractable and well-suited for studying oncogenic signaling, drug responses, and tumor microenvironment interactions. Their robust growth and well-characterized pathways make them an ideal host for CRISPR-based knockout studies.
APOD encodes apolipoprotein D, a lipocalin that transports small hydrophobic ligands and interfaces with multiple signaling cascades. Upstream regulators include PPARG, retinoic acid receptors, estrogen receptor, and glucocorticoids. APOD interacts with APOA1, LCAT, TTR, LRP2, and extracellular matrix components, and modulates downstream effectors such as ERK phosphorylation, NF-??B activation, and JNK signaling through the MAPK/ERK, NF-??B, and PI3K/AKT pathways. By binding LRP2, APOD influences cell survival, differentiation, and inflammatory responses, linking lipid metabolism to oncogenic and neuroprotective processes.
In A-549 cells, APOD knockout disrupts lipid transport and attenuates oncogenic signaling mediated by NF-??B and MAPK, enabling dissection of APOD??s role in tumor progression, metastasis, and drug resistance. This model is particularly valuable for exploring how altered lipid metabolism impacts the lung adenocarcinoma microenvironment and for identifying APOD-dependent mechanisms of chemoresistance. It also facilitates research into retinoid signaling and neuroprotective pathways relevant to cancer-neuronal crosstalk.
These polyclonal knockout cells are compatible with a range of experimental techniques, including western blotting for APOD and key pathway markers (phospho-ERK, NF-??B p65), RT-qPCR for transcript analysis, lipid uptake and transport assays, cell proliferation and migration studies, and apoptosis assays. They are suitable for RNA-seq transcriptomic profiling and co-immunoprecipitation to map APOD interactomes. Applications span cancer biology, lipid metabolism in the tumor microenvironment, neuroprotection research, and investigation of drug resistance mechanisms. For further details, please contact Ascent Research.
